The Board of Directors of Haisco Pharmaceutical Group Co., Ltd. approved the licensing agreement with Nuvectis Pharma, Inc. for HSK42360 and HSK39297. The company will receive upfront and milestone payments totaling up to $1.421 billion, plus sales royalties. The agreement requires shareholder approval.
Summary generated by AI · Always verify with source document
Stock Code: 002653
Stock Abbreviation: Haisco
Announcement No.: 2026-062
Haisco Pharmaceutical Group Co., Ltd.
Announcement of Resolutions of the 40th Meeting of the Fifth Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.